Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placental MSC-derived exosome injection for resistant perianal fistula in Crohn's disease
IRCT20200413047063N3Phase 2Completed
- Sponsor
- Omid Cell and Tissue Processing
- Start
- Jul 2021
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of placental mesenchymal stem cell-derived exosomes in Crohn's disease and inflammatory bowel disease (IBD), sponsored by Omid Cell and Tissue Processing. Primary endpoints: Clinical improvement of fistula, MRI-based fistula healing and 1 more. Started Jul 2021; status: completed.
02
Drugs
placental mesenchymal stem cell-derived exosomes
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on IRCT20200413047063N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200413047063N3.